Alx Oncology Holdings INC

ALX Oncology Holdings Inc. has appointed Scott Garland as Chairman of the Board and Michael Listgarten as General Counsel, with Corey Goodman, Ph.D. stepping down as Chairman.

ALX Oncology Holdings Inc. has entered into a new $50 million secured term loan agreement to refinance existing debt and support general corporate operations.

ALX Oncology Holdings Inc. reported voting results from its Annual Meeting held on June 10, 2026, with key proposals including director elections and executive compensation.

ALX Oncology reported Q1 2026 financial results, highlighting encouraging clinical data for evorpacept in HER2-positive breast cancer and strengthening its leadership team.

ALX Oncology Holdings Inc. announced the appointment of Jeff Knight as Chief Development and Operating Officer, effective April 13, 2026, bringing extensive experience in biopharmaceutical development and operations.

ALX Oncology announced positive full year 2025 financial results, validated its evorpacept biomarker strategy, and extended its cash runway through the first half of 2028 following a $150 million equity offering.

ALX Oncology Holdings Inc. reported its first-quarter 2026 financial results, highlighting a significant reduction in operating expenses and a strong cash position, while continuing to advance its lead product candidate, evorpacept.

ALX Oncology reports a Q3 2025 net loss of $22.1 million, advancing evorpacept and ALX2004 programs while managing significant cash burn and facing regulatory setbacks.

ALX Oncology reported reduced Q2 2025 net losses but announced significant pipeline shifts, including abandoning a U.S. gastric cancer approval path and discontinuing an HNSCC program, while facing Nasdaq delisting risk.

ALX Oncology's Q1 2025 results reveal a net loss, pipeline prioritization, and strategic shifts following Phase 2 trial outcomes, alongside efforts to maintain Nasdaq listing compliance.

ALX Oncology's Q3 2024 report details a net loss of $30.7 million, alongside updates on clinical trials and financial position.

ALX Oncology's second quarter 2024 results show increased R&D spending and a net loss, alongside positive clinical trial updates for their lead product candidate, evorpacept.

ALX Oncology's 10-K filing highlights positive Phase 2 clinical data for evorpacept and outlines plans for new clinical trials in breast and colorectal cancer.

ALX Oncology's 10-K filing outlines the company's capital structure, including common and preferred stock, and details registration rights for certain shareholders.

Shelly Wong, SVP, Finance and CAO of ALX Oncology Holdings Inc., reported a sale of 1,404 common shares on July 1, 2026, to cover tax obligations related to vesting restricted stock units.

Chief Development and Operating Officer Jeff E. Knight was granted 800,000 stock options in ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc. Chief Medical Officer Barbara Klencke was granted 100,000 stock options on April 16, 2026.

ALX Oncology Holdings Inc. CEO Jason Lettmann sold 12,311 shares of common stock to cover tax obligations from vested restricted stock units.

ALX Oncology Holdings Inc.'s SVP of Finance and CAO, Shelly Pinto, sold 903 shares of common stock to cover tax obligations related to vested restricted stock units.

ALX Oncology Holdings Inc.'s Chief Medical Officer, Barbara Klencke, was granted 700,000 stock options with an exercise price of $2.07 per share.

ALX Oncology Holdings Inc. has scheduled its 2026 Annual Meeting of Stockholders for June 10, 2026, to conduct routine governance and compensation votes.

ALX Oncology Holdings Inc. will hold its 2025 Annual Meeting of Stockholders virtually on June 11, 2025, to elect directors, conduct an advisory vote on executive compensation, and ratify the appointment of KPMG LLP as its independent accounting firm.

ALX Oncology Holdings Inc. reports the resignations of two board members and subsequent adjustments to board committees and director classifications.

ALX Oncology Holdings Inc. will hold its 2024 Annual Meeting of Stockholders virtually on June 12, 2024, to vote on director elections, executive compensation, and the ratification of the company's independent auditor.

Lightstone Ventures and associated entities have filed an amendment to their Schedule 13D, reporting a decrease in their beneficial ownership percentage of ALX Oncology Holdings Inc. due to share dilution.

venBio Global Strategic Fund II L.P. acquired over 3 million shares in ALX Oncology Holdings Inc.'s recent follow-on offering, increasing key investors' beneficial ownership to 10%.

HBM Healthcare Investments (Cayman) Ltd. has filed an amendment reporting beneficial ownership of 6.5% of ALX Oncology Holdings Inc. common stock.

Millennium Management and affiliated entities report a 1.5% beneficial ownership stake in ALX Oncology Holdings Inc.

RA Capital Management and its affiliates have disclosed a 9.9% beneficial ownership stake in ALX Oncology Holdings Inc., totaling 13,117,106 shares.

TCG Crossover Funds and Chen Yu have disclosed a combined 9.9% beneficial ownership stake in ALX Oncology Holdings Inc. following a recent underwritten offering.

Tang Capital Management and its affiliates have reported a complete divestment of their beneficial ownership in ALX Oncology Holdings Inc., now holding 0% of the common stock.

Tang Capital Management and its affiliates have reported a complete divestment of their beneficial ownership in ALX Oncology Holdings Inc., now holding 0% of the common stock.